Myriocin: Selective SPT Inhibitor for Sphingolipid Metabolism & Oncology Research

Executive Summary: Myriocin (CAS 35891-70-4) is a crystalline, highly potent inhibitor of serine palmitoyltransferase (SPT), exhibiting a Ki of 0.28 nM and 98% purity (APExBIO, product page). It suppresses sphingolipid biosynthesis, leading to immunosuppressive and antiproliferative effects in vitro and in vivo (He et al., 2025). Myriocin reduces tumor formation in murine melanoma models and inhibits lung cancer cell lines A549 and NCI-H460 with IC50 values of 30 μM and 26 μM, respectively. It also restores metabolic homeostasis and modulates mitochondrial function via AMPK-PGC1α pathways (He et al., 2025). The compound is widely used in research on sphingolipid metabolism, oncology, and immunology.

Biological Rationale

Sphingolipids are essential bioactive molecules involved in membrane structure and signaling. Dysregulation of sphingolipid metabolism has been implicated in metabolic disorders, cancer progression, and immune dysfunction [1]. Serine palmitoyltransferase (SPT) is the enzyme catalyzing the initial and rate-limiting step in de novo sphingolipid biosynthesis. Inhibiting SPT disrupts ceramide and sphingolipid production, affecting cell growth, apoptosis, and immune responses [2]. Myriocin’s high affinity and selectivity for SPT make it a preferred tool for dissecting these pathways in experimental models.

Mechanism of Action of Myriocin

Myriocin acts as a structural analog of sphinganine and irreversibly inhibits SPT by binding to its active site. This inhibition blocks the condensation of serine and palmitoyl-CoA, preventing the synthesis of 3-ketodihydrosphingosine—the first committed intermediate in sphingolipid biosynthesis [3]. As a result, downstream ceramide, sphingomyelin, and glycosphingolipid levels are reduced. Through these actions, Myriocin modulates cell proliferation, apoptosis, and immune cell function. It also influences metabolic pathways through crosstalk with AMPK-PGC1α signaling, promoting mitochondrial biogenesis and thermogenesis [1].

Evidence & Benchmarks

• Myriocin inhibits SPT activity with a Ki of 0.28 nM in vitro (APExBIO data, APExBIO).
• In A549 and NCI-H460 lung cancer cell lines, Myriocin shows dose-dependent inhibition of cell growth with IC50 values of 30 μM and 26 μM in serum-containing media (He et al. 2025, DOI).
• In vivo, Myriocin reduces tumor formation and modulates cell cycle regulators (Cdc25C, Cdc2, cyclin B1) and tumor suppressors (p53, p21) in murine melanoma models (He et al. 2025, DOI).
• Myriocin administration in mice on a high-AGE diet led to a 76% reduction in body weight gain, 44.5% reduction in fasting glucose, and significant lowering of serum LDL-C, TG, and TC (by 52.3%, 51.8%, and 48.8%, respectively) over 24 weeks (He et al. 2025, DOI).
• Myriocin increases mitochondrial biogenesis (2.1-fold increase in mtDNA) and upregulates Ucp1, enhancing thermogenesis in adipose tissue (He et al. 2025, DOI).

This article extends the scenario-focused protocol guidance in "Myriocin (SKU B6064): Advanced SPT Inhibition for Reproducibility" by integrating metabolic and oncological endpoints, and updates "Myriocin and the New Frontier in Sphingolipid Metabolism" with new in vivo metabolic data (He et al., 2025). For a summary of immunosuppressive mechanisms, see "Myriocin: Selective Serine Palmitoyltransferase Inhibitor...".

Applications, Limits & Misconceptions

Myriocin is widely utilized in:

• Sphingolipid metabolism research: Dissecting ceramide pathways and metabolic regulation.
• Cancer research: Studying cell cycle arrest, tumor suppressor activation, and antiproliferative effects.
• Immunology: Probing T cell activation, immunosuppression, and autoimmune models.
• Metabolic disease models: Investigating obesity, glucose, and lipid homeostasis in murine models exposed to high-AGE diets.

Common Pitfalls or Misconceptions

• Myriocin is not suitable for long-term solution storage; solutions degrade and should be used promptly (APExBIO, product page).
• It is not a pan-ceramide inhibitor—Myriocin specifically targets SPT and does not inhibit downstream sphingolipid enzymes.
• Myriocin is not intended for human or veterinary therapeutic use; strictly for research purposes.
• Results may vary across species, cell lines, and experimental conditions; optimization is required for each context.
• Improper storage above -20°C or exposure to moisture may reduce product purity and activity.

Workflow Integration & Parameters

Myriocin (B6064) from APExBIO is provided as a crystalline solid (MW 401.54, C21H39NO6). It is soluble up to 2 mg/mL in methanol. For cell-based assays, typical working concentrations range from 1–50 μM, with IC50 benchmarks for A549 (30 μM) and NCI-H460 (26 μM) in serum-containing medium. Animal dosing in metabolic studies follows published protocols (e.g., 0.3 mg/kg in C57BL/6J mice, 24 weeks) [1]. Store powder at -20°C in a desiccated environment; ship on blue ice. Avoid repeated freeze-thaw cycles and prepare fresh solutions for each use. Refer to the APExBIO Myriocin product page for lot-specific details.

Conclusion & Outlook

Myriocin is a gold-standard tool for mechanistic dissection of sphingolipid metabolism, cancer biology, and metabolic disease models. It provides robust, dose-dependent inhibition of SPT, enabling precise modulation of ceramide and downstream sphingolipid levels. Recent evidence supports its role in metabolic reprogramming and mitochondrial activation via AMPK-PGC1α signaling. As new in vivo benchmarks emerge, Myriocin remains central for translational research targeting sphingolipid-driven pathologies. For advanced protocol strategies and troubleshooting, see the APExBIO Myriocin B6064 kit and related technical articles.